Liposome Drug Delivery Market Analysis by Product (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B); Technology (Stealth, Non-PEGylated, DepoFoam Liposome Technology); Application (Fungal Diseases, Pain Management, Cancer Therapy, Viral Vaccines, Photodynamic Therapy) – Global Supply & Demand Analysis & Opportunity Outlook 2023 – 2035
Buy Now Report ID: 4073 | Published Date: May 01, 2023
Liposome Drug Delivery Market size is estimated to reach ~USD 10 billion by the end of 2035 by growing at a CAGR of ~9% over the forecast period, i.e., 2023 – 2035. In addition to this, in the year 2022, the market size of liposome drug delivery was ~USD 5 billion. The growth of this market can be attributed to the growing demand for effective and efficient therapeutics considering the growing cases of chronic disease all over the world. Also, liposome-based drug delivery methods contain certain advantages as compared to other delivery systems. As a result, drugs are encapsulated into liposomes for effective delivery. According to World Health Organization, 41 million people lose their life owing to chronic disease every year which is equivalent to 74% of death globally.
In addition, increasing advances in liposomal drug delivery methods owing to new investments and ongoing R&D activities, product launches, mergers and acquisitions, and collaborations among major market players, are driving the growth of liposomal drug delivery expected to drive further growth of the market. Moreover, various government authorities have been seen offering funds and investments for the research and development activities of the liposome drug delivery market. For instance, in 2019, the NIH awarded researchers at the University of Massachusetts Amherst a USD 1.7 million grant to develop new liposome-based vaccine delivery systems.
|
Base Year |
2022 |
|
Forecast Year |
2023 – 2035 |
|
CAGR |
~9% |
|
Base Year Market Size (2022) |
~USD 5 billion |
|
Forecast Year Market Size (2035) |
~USD 10 billion |
|
Regional Scope |
|
Growth Drivers
Challenges
The global liposome drug delivery market is segmented and analyzed for demand and supply by application into fungal diseases, pain management, cancer therapy, viral vaccines, photodynamic therapy, and others. Out of these, the cancer therapy segment is anticipated to hold the largest market share by the end of 2035. This can be attributed to the high prevalence of cancer and the growing demand for advanced therapeutics. Over the years, the prevalence of cancer has been seen to increase rapidly which is expected to drive the growth of the cancer therapy segment. As cancer is one of the diseases which attracts more attention from the R&D owing to its high prevalence and seriousness, this segment is anticipated to grow in the upcoming times. According to a report, there were approximately 19.3 million new cancer diagnoses worldwide in 2020, with breast cancer being the most common cancer, followed by lung cancer.
The global market is segmented and analyzed for demand and supply by-products into liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. Out of these, the liposomal doxorubicin segment is anticipated to hold the largest market share by the end of 2035. This segment includes liposomes that are used to deliver the chemotherapy drug doxorubicin. Liposomal doxorubicin is effective in treating certain types of cancer, such as ovarian and breast cancer.
Our in-depth analysis of the global liposome drug delivery market includes the following segments:
|
By Product |
|
|
By Technology |
|
|
By Application |
|
The market in North America is projected to garner the largest revenue by the end of 2035. The growth of the market in the region can primarily be attributed to the increasing prevalence of cancer in the region, followed by the surge in government initiatives that promote research and development for cancer drugs and drug delivery systems, along with the surge in healthcare expenditure in the region. According to the statistics by the National Cancer Institute (NCI), in the year 2020, the new cases of cancer that were expected to be diagnosed in the United States were about 1806590 cases. The statistics also stated that during the same year, 606520 people were expected to die as a result of the disease.
On the other hand, the liposome drug delivery market in Europe is projected to garner the second-largest revenue by the end of 2035. The market in the region is further segmented by country into Germany, France, United Kingdom, Italy, Spain, and the Rest of Europe. The market in Germany is projected to garner the second-largest revenue by the end of 2035. The market is driven by the increasing prevalence of chronic diseases such as cancer and cardiovascular diseases that require targeted drug delivery systems. Additionally, the rising demand for personalized medicine and the need for improved drug efficacy and safety are driving market growth. The market for liposome delivery in Europe is highly regulated with stringent safety and efficacy guidelines. Companies operating in the market must comply with these regulations to obtain approval for their products. The European liposomal drug delivery market is expected to continue growing in the coming years, driven by increasing demand for targeted drug delivery systems and personalized medicine.
Liposome drug delivery market in the Asia Pacific is anticipated to account for a significant market share by the end of 2035. The market is driven by the increasing prevalence of chronic diseases such as cancer and cardiovascular diseases that require targeted drug delivery systems. Additionally, the rising demand for personalized medicine and the need for improved drug efficacy and safety are driving market growth. The Asia-Pacific liposome delivery market is expected to continue growing in the coming years, driven by increasing demand for targeted drug delivery systems and personalized medicine. Moreover, the development of new liposome technologies and growing interest in drug delivery in the pharmaceutical industry are expected to further drive market growth.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: The rising prevalence of cancer globally, and the increasing application of liposomes as a drug delivery system are some of the major factors anticipated to drive market growth.
Ans: The market size of capsaicin is anticipated to attain a CAGR of ~9% over the forecast period, i.e., 2023 – 2035.
Ans: The high cost of development of the drug delivery system is one of the major factors estimated to hamper the market growth.
Ans: North America is estimated to create notable growth opportunities for market growth over the forecast period.
Ans: The major players in the market are Sciences, Inc., Celsion Corporation, Ipsen Pharma, Pacira Pharmaceuticals, Inc., Novartis AG, CordenPharma International, FUJIFILM Toyama Chemical Co., Ltd., and Others.
Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by application, product, technology, and by region.
Ans: The liposomal doxorubicin segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
